Kyntra Bio, Inc.
KYNB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000921299
No open-market purchases or sales by Kyntra Bio, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $7.54M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Kyntra Bio, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 30 | 32 | +2 |
| Shares | 1.06M | 1.13M | +72.2K (+6.8%) |
| Value | $5.62M | $13.9M | +$8.25M (+146.9%) |
New holders (4)
Institutions that held Kyntra Bio, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 23,517 | $288.1K | 0.00% |
| Squarepoint Ops LLC | 16,370 | $200.5K | 0.00% |
| DRW Securities, LLC | 11,215 | $137.4K | 0.01% |
| Citigroup Inc | 2,168 | $26.6K | 0.00% |
Sold out (2)
Institutions that held Kyntra Bio, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Connective Capital Management, LLC | 15,000 | $79.5K |
| GFG Capital, LLC | 507 | $2.69K |